Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator
BEIJING & SHANGHAI & HONG KONG — Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stoc
(Financial Post, 2025-12-10T02:50:39Z)